the ovalbumin-induced (oVA) chronic allergic airways murine model is a well-established model for investigating pre-clinical therapies for chronic allergic airways diseases, such as asthma. Here, we examined the effects of several experimental compounds with potential anti-asthmatic effects including resveratrol (RV), relaxin (RLN), l-sulforaphane (LSF), valproic acid (VPA), and trichostatin A (TSA) using both a prevention and reversal model of chronic allergic airways disease. We undertook a novel analytical approach using focal plane array (fpA) and synchrotron fourier-transform infrared (S-ftiR) microspectroscopic techniques to provide new insights into the mechanisms of action of these experimental compounds. Apart from the typical biological effects, S-FTIR microspectroscopy was able to detect changes in nucleic acids and protein acetylation. Further, we validated the reduction in collagen deposition induced by each experimental compound evaluated. Although this has previously been observed with conventional histological methods, the S-FTIR technique has the advantage of allowing identification of the type of collagen present. More generally, our findings highlight the potential utility of S-ftiR and fpA-ftiR imaging techniques in enabling a better mechanistic understanding of novel asthma therapeutics. Animal models designed specifically for chronic lung diseases such as asthma are important for investigating the underlying mechanisms of the disease and the effectiveness of potential novel therapies 1. One of the most widely used models for asthma is the mouse chronic allergic airways disease model that utilises ovalbumin (OVA) 2,3. This model recapitulates many of the hallmark characteristics of chronic asthma including eosinophilic inflammation, airway hyperresponsiveness, epithelial wall thickening, goblet cell metaplasia, and fibrosis 4,5 .